# Route-finding workflow: imidazo[1,2-b]pyridazine case study

**Prepared:** 10 October 2026  
**Purpose:** Document how the previously proposed routes were obtained, and provide a concrete baseline for comparison with a tool-based retrosynthesis workflow.  
**Status:** Literature-supported route proposals; no experimentally verified synthesis of the exact target was established.

## 1. What this workflow actually was

The delivered answer used **LLM-guided chemical planning, public text-based literature/patent retrieval, and RDKit structure checks**. It was not the output of a dedicated retrosynthesis engine or a structure-indexed reaction database.

```text
Target SMILES
    ↓
Identify the molecular graph, core, substitution pattern, and linker connectivity
    ↓
Seek an exact preparation; broaden to scaffold and transformation precedents
    ↕
Develop a core-construction strategy and explicit precursor structures
    ↓
Evaluate what each retrieved example supports—and what remains extrapolation
    ↓
Assemble a connected route and a finishing alternative
    ↓
Rank qualitatively; flag the shared bottleneck and unverified steps
    ↓
Check molecular structures with RDKit
    ↓
Generate structure-resolved SVG/HTML with evidence labels
```

This is a **high-level reconstruction of the documented process**, not a verbatim or timestamped search log. The original literal search queries and a complete rejected-candidate history are not available in this document. Queries in Section 4 are suggested equivalents for replay, not claimed historical tool calls. The stage order is a logical workflow; planning and retrieval are iterative rather than strictly sequential.

**Additional work during preparation of this document:** the five cited patent HTML texts were revisited, their relevant passages located, and the nine structures stored in the delivered HTML were checked again with local RDKit 2025.09.4. These are documentation-pass checks, not additional original route-search results.

## 2. Input and structural specification

**Original input**

```smiles
Cc(n1)c(Cc2ccccc2)n3c1c(CN4CCNCC4)cc(OC)n3
```

**Canonical representation in the delivered files**

```smiles
COc1cc(CN2CCNCC2)c2nc(C)c(Cc3ccccc3)n2n1
```

The two representations give the same canonical isomeric SMILES under the installed RDKit version. The graph—not the generated chemical name—is the identity reference.

| Structural feature | Requirement for route construction |
|---|---|
| Imidazo[1,2-b]pyridazine core | Preserve the fused-ring connectivity and nitrogen positions. |
| C2 methyl and C3 benzyl | Install **CH₃** and **CH₂Ph** at the correct positions; benzyl is not phenyl. |
| C6 methoxy | Retain the C–O–CH₃ connectivity. |
| C8 piperazinylmethyl | The required connection is **core–CH₂–N**, not core–N. |
| Other piperazine nitrogen | It is NH in the target, not methylated or permanently protected. |
| Neutral input | Distinguish the depicted free base from an acid salt isolated after deprotection. |

The most consequential early structural check was the **one-carbon linker at C8**. A direct heteroaryl amination could give a valid molecule while giving the wrong target.

## 3. Tools and division of responsibility

| Component | Role in this case | What it did not establish |
|---|---|---|
| LLM chemical analysis | Identified the core, proposed intermediates, assembled steps, and assessed qualitative risks. | Experimental feasibility or calibrated success probabilities. |
| Public web/patent search | Retrieved named scaffolds, transformations, experimental examples, and previously reported catalogue pointers. | Exhaustive coverage of patents or structure-indexed exact/substructure retrieval. |
| Reading experimental text | Connected individual precedent claims to particular examples and steps. | That the exact target substrates behave like the cited analogues. |
| Python + RDKit | Parsed SMILES, canonicalized structures, calculated graph-derived properties, and generated molecular depictions. | Reaction success, regioselectivity, mechanism, yield, or complete atom provenance. |
| SVG/HTML generation and browser inspection | Presented structures, conditions, references, and route navigation. | Chemical validation of the arrows between structures. |

**Not used to generate the delivered routes:** an ASKCOS/AiZynthFinder/Syntheseus route-search run, a Reaxys/SciFinder/Pistachio database query, a reaction-atom-mapping engine, a forward-reaction model, or a live inventory/pricing API. The comparison baseline is therefore **reasoning + text retrieval + molecular graph checks**, not an automated template-search baseline.

## 4. Retrieval strategy and reproducible query examples

### 4.1 Search at progressively broader levels

The search outcome reported previously was that **a verified preparation of the exact target was not located in the public sources searched**. This is a limited retrieval result—not proof that the compound or its synthesis is absent from the literature.

A reproducible search plan should distinguish four levels:

| Level | Search objective | Suggested equivalent query—not an original query log |
|---|---|---|
| Exact structure/name | Find an experimental preparation of the target. | `"3-benzyl" "6-methoxy" "piperazin" "imidazo" "pyridazine"` |
| Closely substituted core | Find the ring system with the relevant side-chain position or synthetic handle. | `"imidazo[1,2-b]pyridazine" "8-carboxylate"` |
| Core construction | Establish where precursor atoms and substituents appear after annulation. | `"3-amino-6-chloro" "pyridazine-4-carboxylic" "chloroacetaldehyde"` |
| Transformation-specific | Find experimentally described conversions for unresolved steps. | `"imidazo" "pyridazine" "hydroxymethyl" "sodium borohydride"` |

Additional useful query formulations for this case are:

```text
"aminopyridazine" "bromo(phenyl)acetyl" "isopropanol"
"6-Methoxyimidazo" "Sodium methoxide"
"imidazo" "pyridazine" "benzaldehyde" "triacetoxyborohydride"
"3-bromo-4-phenylbutan-2-one"
```

Exact SMILES can be tried as text, but a negative text hit is not a molecular-structure search result. Name variants, punctuation, and extracted-text errors also matter. For example, the secondary-bromoketone patent renders intermediate labels as `lnt-4`/`lnt-5`, which can defeat a literal `Int-4` search. [S2]

### 4.2 Extract evidence from the experimental section

For each useful hit, retain the **actual substrate description, product description, example locator, conditions, and scope limitation**. A patent title or a search-result snippet alone is not sufficient evidence for a specific transformation.

The original answer assembled complementary examples from several documents. It did **not** recover one patent containing the full proposed target route.

## 5. How the principal core-construction strategy was assembled

The selected plan places an **ester at the eventual C8 position before ring construction** and then uses that carbon as the precursor of the aminomethyl linker.

```text
A = ethyl 3-amino-6-chloropyridazine-4-carboxylate
B = CH₃CO–CH(Br)–CH₂Ph

A + B → I1

I1 = 2-Me / 3-CH₂Ph / 6-Cl / 8-CO₂Et imidazo[1,2-b]pyridazine
```

Two different pieces of evidence support different aspects of this proposal:

**Positional scaffold evidence.** WO2009077334A1, Examples 8–9, describes the aminopyridazine ester and its annulation with **chloroacetaldehyde** to the C8-carboxylate fused core. This supports the ester-position relationship, but not the proposed secondary bromoketone. [S1]

**Reaction-partner evidence.** WO2012136776A1, Intermediate Examples Int-4/Int-5, describes secondary α-bromoketone annulations with substituted aminopyridazines. Those ketones have an α-phenyl substituent and different carbonyl-side substituents; the aminopyridazines also differ from A. This supports a reaction class, not the exact A + B combination. [S2]

The proposed positional correspondence is:

| Precursor feature | Intended product feature |
|---|---|
| Carbonyl carbon of B, bearing CH₃ | C2 bearing methyl |
| α-Bromo carbon of B, bearing CH₂Ph | C3 bearing benzyl |
| C4 ester of A | C8 ester of I1 |
| C6 chloride of A | C6 chloride of I1 |

**This correspondence is a chemical interpretation, not an atom-mapper result.** No complete atom-mapped reaction or experimentally demonstrated regioselectivity was produced for A + B.

The crucial inference is that the two precedents might be combined. The crucial limitation is that **evidence for each feature separately does not prove their joint compatibility**. This annulation is the shared route bottleneck.

## 6. Route assembly and ordering

The ester supplies a controlled C8 functional handle, rather than requiring an unverified direct late-stage installation of the whole aminomethyl substituent.

```text
Shared sequence:
A + B → I1 → I2 → I3
         │     │     │
       6-Cl  6-OMe  8-CH₂OH
       8-ester throughout I1/I2

Route 1:
I3 → I4 (8-CHO) → I5 (Boc-protected target) → T
     oxidation    reductive amination       deprotection

Route 2:
I3 → M (8-CH₂OMs) → I5 (Boc-protected target) → T
     activation     displacement              deprotection
```

The sequence incorporates three planning decisions, rather than experimentally established optimizations: introduce methoxy before piperazine; use **mono-Boc-piperazine** to control its substitution state; and remove Boc at the end. The ethyl ester drawn as I2 is one explicit structure—possible methyl-ester formation in methanolic methoxide was flagged, not experimentally established.

The earlier suggestion to methoxylate A **before** annulation is an order-of-operations contingency. It was not developed into a third fully specified and independently supported route.

### Route diversity and step count

These are **two finishing variants of one strategic family**. They share the first three transformations and the final deprotection; only the two operations between I3 and I5 differ. Both depend on the same unresolved annulation and ester reduction.

Each displayed route has **six transformations**, conditional on starting from A, B, and the required protected piperazine. That is not a demonstrated six-operation laboratory process: precursor manufacture, isolation, purification, salt conversion, and failed optimization experiments are not included. There are **eight unique proposed transformations** across the combined map.

## 7. Step-level evidence assessment

The categories below describe provenance, not calibrated probabilities:

- **Exact:** an experimental example for the proposed substrate-to-product conversion.
- **Analogue:** experimental evidence for a related conversion, with differences recorded explicitly.
- **Proposal:** a chemically motivated conversion without a located substrate-specific precedent.

No exact-substrate experimental preparation was established for any of the eight proposed transformations.

| Transformation | Evidence used | Boundary of the evidence |
|---|---|---|
| A + B → I1, annulation | Complementary analogues: S1 + S2 | Positional support and secondary-bromoketone support come from different substrate combinations. |
| I1 → I2, methoxylation | Related core: S3 | Does not establish the behavior of this C2/C3/C8-substituted substrate or its ester identity after workup. |
| I2 → I3, ester reduction | Related C8 ester: S4 | The precedent is a **methyl ester with a C7-NHBoc substituent**, not I2. NaBH₄/MeOH is a substrate-dependent hypothesis here, not a universal ester-reduction method. |
| I3 → I4, oxidation | Proposal | Exact-substrate conversion and aldehyde stability remain unverified. |
| I4 → I5, reductive amination | Broad compatibility analogue: S5 | The cited aldehyde is on an attached phenyl ring, and the amines differ; it is not direct evidence for a C8 aldehyde plus N-Boc-piperazine. |
| I3 → M, mesylation | Proposal | Exact-substrate conversion and mesylate stability remain unverified. |
| M → I5, displacement | Proposal | The required selective N-alkylation has not been demonstrated on M. |
| I5 → T, deprotection | Proposal | Exact-substrate outcome and isolated salt/free-base form remain unverified. |

### Conditions were hypotheses, not copied target protocols

The condition suggestions in the earlier answer had different origins. iPrOH-based annulation, methoxide substitution, and the initial borohydride screen drew on analogues. Alcohol oxidation, mesylation, displacement, deprotection, and several backup choices were standard-transformation proposals. None supplied a target-specific yield.

A comparison system should keep **reported analogue conditions**, **proposed target conditions**, and **measured target outcomes** in different fields. It should not silently transfer an analogue yield or turn an incomplete condition suggestion into an executable procedure. [S1], [S2], [S3], [S4], [S5]

## 8. Ranking and uncertainty

Route 1 was preferred qualitatively because its finishing sequence avoids making a reactive heteroarylmethyl leaving group. Route 2 was retained as an alternative that avoids aldehyde preparation and handling. These are planning judgments; no comparative experiment or calibrated route score established that one is superior.

The major unresolved questions are whether A and B annulate as intended, whether the substituted ester reduces selectively, and whether the selected finishing branch behaves as proposed. A finishing alternative does **not** protect against failure of a shared upstream step.

The original prioritization therefore remained: **test the common A + B → I1 transformation before treating either route as experimentally supported**. This is a development priority, not an execution authorization.

## 9. What the structure and visualization checks proved

The delivered HTML stores nine unique main structure records: **A, B, I1, I2, I3, I4, M, I5, T**. N-Boc-piperazine appears in the conditions rather than as an additional main structure card.

The documentation-pass audit extracted these records from the HTML and confirmed:

| Check | Result | Meaning |
|---|---|---|
| SMILES parsing with RDKit 2025.09.4 | 9/9 passed | All nine stored structures are accepted molecular graphs. |
| Target canonical isomeric SMILES comparison | Passed | T matches the input under the same RDKit representation. |
| Identifiers in both route sequences | All resolve | Both sequences refer to defined structure records. |

The prior visualization stage used SMILES-derived molecular drawings in composed SVG/HTML. Browser checks concerned layout and interactions; they were not forward-reaction validation.

**Not proved by these checks:** that each arrow produces the depicted product; atom conservation across a fully specified reaction; reaction-center selectivity; actual ester identity; stability; yield; purity; orderability; or laboratory safety. Valid molecules at both ends of an arrow do not validate the arrow.

## 10. Comparison with your tool-based workflow

The right comparison is not “LLM versus tools,” because this baseline also used tools. It is **reasoning-led text retrieval versus a more structured route-generation and validation pipeline**. The third column below is a measurement plan, not an assumption about your implementation.

| Dimension | Baseline in this case | What to record for your workflow |
|---|---|---|
| Target identity | RDKit graph check | Normalization policy, stereochemistry handling, and exact graph identity. |
| Candidate generation | LLM proposals guided by text precedents | Candidate source, model/template version, search settings, and failures. |
| Precedent retrieval | Public experimental text | Exact/analogue matches, reaction-center similarity, example locators, and contradictory evidence. |
| Atom provenance | Chemical interpretation | Mapping validity and preservation of the C8 linker carbon and C2/C3 substituent identities. |
| Route continuity | Explicit intermediates and identifier checks | Product–next-reactant consistency and complete protection-state tracking. |
| Feasibility | Qualitative risk assessment | Substrate-aware checks, forward-model results if used, and unresolved chemical objections. |
| Starting materials | Previous catalogue pointers, not a stock-closed route | Exact inventory matches, supplier identifiers, availability date, quantities, price, and lead time. |
| Diversity | Two variants; one core strategy | Both unique full routes and distinct strategic families. |
| Quantitative confidence | Not calibrated | Score provenance and calibration evidence; keep unknown probabilities unknown. |
| Reproducibility | Artifacts and source pointers; incomplete original query history | Full queries, tool responses, versions, budgets, and run logs. |

### Case-specific failure tests

Reject or flag a generated route that loses the C8 methylene, substitutes phenyl for benzyl at C3, changes the fused-ring nitrogen topology, leaves the wrong piperazine protection state, or treats the ester position as interchangeable. Also flag a correct-looking route that imports an analogue yield as a target yield or declares terminal precursors “available” without inventory evidence.

For a fair benchmark, use the same target representation, precursor inventory, permitted step count, and search budget. Report structural validity, route continuity, step-level evidence, useful strategic diversity, unresolved bottlenecks, and chemist acceptance separately. Do not infer experimental success from a computational “solved” flag.

Original search cost and complete tool-call counts were not retained here; this case should not be used for a precise latency or cost comparison without a new instrumented replay.

## 11. Suggested step record for a tool-based implementation

The following is a **proposed logging format**, created for comparison. It is not a record emitted by the original search system. The reaction SMILES is an unmapped planning representation; it omits auxiliary reagents and byproducts and is not an atom-balanced executable specification.

```json
{
  "step_id": "common_1",
  "strategic_family": "aminopyridazine_secondary_alpha_bromoketone_annulation",
  "input_ids": ["A", "B"],
  "output_id": "I1",
  "reaction_smiles_unmapped": "CCOC(=O)c1cc(Cl)nnc1N.CC(=O)C(Br)Cc1ccccc1>>CCOC(=O)c1cc(Cl)nn2c(Cc3ccccc3)c(C)nc12",
  "evidence_category": "complementary_analogues",
  "evidence": [
    {
      "source_id": "S1",
      "locator": "Examples 8–9",
      "supports": ["C4 precursor ester becomes C8 fused-core ester"],
      "does_not_establish": ["annulation with secondary bromoketone B"]
    },
    {
      "source_id": "S2",
      "locator": "Intermediate Examples Int-4 and Int-5",
      "supports": ["secondary alpha-bromoketone annulation class"],
      "does_not_establish": ["exact A + B combination"]
    }
  ],
  "condition_origin": "adapted_from_analogues",
  "exact_substrate_experiment_verified": false,
  "molecular_smiles_parse": true,
  "atom_mapping_status": "not_performed",
  "forward_prediction_status": "not_performed",
  "starting_material_live_stock_status": "not_verified",
  "target_step_yield": null,
  "calibrated_success_probability": null,
  "review_status": "requires_chemical_and_experimental_validation"
}
```

Keep source evidence immutable and separate from proposed edits. A strengthened workflow would retrieve structure-indexed precedents, validate atom provenance and route continuity, check the exact inventory, and then reassess the chemistry. These are proposed additions—not capabilities retrospectively attributed to the original run.

## 12. Structure registry for replay

These are the structures used in the supplied route files. I2 is the **drawn ethyl ester**, not a claim that ester exchange is absent.

```text
A
CCOC(=O)c1cc(Cl)nnc1N

B
CC(=O)C(Br)Cc1ccccc1

I1
CCOC(=O)c1cc(Cl)nn2c(Cc3ccccc3)c(C)nc12

I2
CCOC(=O)c1cc(OC)nn2c(Cc3ccccc3)c(C)nc12

I3
COc1cc(CO)c2nc(C)c(Cc3ccccc3)n2n1

I4
COc1cc(C=O)c2nc(C)c(Cc3ccccc3)n2n1

M
COc1cc(COS(C)(=O)=O)c2nc(C)c(Cc3ccccc3)n2n1

I5
COc1cc(CN2CCN(C(=O)OC(C)(C)C)CC2)c2nc(C)c(Cc3ccccc3)n2n1

T
COc1cc(CN2CCNCC2)c2nc(C)c(Cc3ccccc3)n2n1

Auxiliary coupling partner: N-Boc-piperazine
CC(C)(C)OC(=O)N1CCNCC1
```

## 13. Source register and associated artifacts

The following **experimental text locations** were checked during this documentation pass. A source supports only the stated feature, not the complete target synthesis. This was an HTML-text verification, not a fresh PDF-scheme or spectral-data audit.

| ID | Primary source | Experimental locator | Specific use |
|---|---|---|---|
| S1 | [WO2009077334A1][S1] | Examples 8–9 | Aminopyridazine ester and C8-carboxylate core construction with chloroacetaldehyde. |
| S2 | [WO2012136776A1][S2] | Intermediate Examples Int-4/Int-5; extracted text uses `lnt` | Secondary α-bromoketone annulations on different substituted aminopyridazines. |
| S3 | [WO2021023858A1][S3] | Example 10, Step 1 | Related-core C6 chloride-to-methoxy conversion. |
| S4 | [WO2021000855A1][S4] | Example 53, Step 4 | C8 methyl ester-to-alcohol conversion on a C7-NHBoc analogue. |
| S5 | [WO2013134219A1][S5] | Section 5.6.13, Part B; Section 5.6.16 | Reductive amination of pendant benzaldehydes; broad compatibility evidence only. |

Source quantities and text quality still require checking before any experimental recipe is transcribed. Analogue yields were deliberately not used as forecasts for this target.

Associated files from the preceding answer, using relative links:

| Artifact | File |
|---|---|
| Interactive route explorer | [synthesis_routes.html](synthesis_routes.html) |
| Combined route map | [synthesis_routes_overview.svg](synthesis_routes_overview.svg) |
| Route 1 | [synthesis_route_1.svg](synthesis_route_1.svg) |
| Route 2 | [synthesis_route_2.svg](synthesis_route_2.svg) |

Keep these files beside this Markdown file for the relative links to work locally.

## 14. Main lesson for the comparison

The useful feature of this workflow is **assembling a scaffold-specific strategy from complementary precedents while retaining explicit molecular structures**. Its main weakness is the distance between those precedents and the exact proposed reactions.

A stronger tool-based workflow should make that distance measurable and auditable—not merely generate more route trees. In this case, the decisive questions are whether it finds better support for **A + B → I1**, validates the C8-handle transformations, and verifies the actual starting materials. Two visually different finishing branches do not resolve an unsupported shared core construction.

[S1]: https://patents.google.com/patent/WO2009077334A1/en
[S2]: https://patents.google.com/patent/WO2012136776A1/en
[S3]: https://patents.google.com/patent/WO2021023858A1/en
[S4]: https://patents.google.com/patent/WO2021000855A1/en
[S5]: https://patents.google.com/patent/WO2013134219A1/en
